According to the World Health Organization, Acinetobacter, the representative of the ESCAPE group, ranks first among the sexually transmitted patients. For many years in the treatment, carbapenems were formed by the initial selection group. Unfortunately, the resistance to carbapenems is rapidly increasing among representatives of the Acinetobacter genus. The aim of the study was to determine the frequency of Acinetobacter gene isolated from patients applying to Medical University Clinics and Central Military Clinical Hospital and investigate the profile of sensitivity to antibiotics.
Bergogne-Bérézin E, Joly-Guillou ML, Vieu JF. Epidemiology of nosocomial infections due to Acinetobacter calcoaceticus. J Hosp Infect. 1987 Sep;10(2):105–113.
Bouvet PJ, Grimont PA. Identification and biotyping of clinical isolates of Acinetobacter. Ann Inst Pasteur Microbiol. 1987 Sep-Oct;138(5):569–578.
Freney J, Bouvet PJ, Tixier C. Identification et détermination de la sensibilité aux antibiotiques de 31 souches cliniques d'Acinetobacter autres que A. baumannii. Ann Biol Clin (Paris) 1989;47(1):41–44.
Glew RH, Moellering RC, Jr, Kunz LJ. Infections with Acinetobacter calcoaceticus (Herellea vaginicola): clinical and laboratory studies. Medicine (Baltimore) 1977 Mar;56(2):79–97.
Hercouet H, Bousser J, Donnio PY, Avril JL. Activité in vitro des antibiotiques sur les souches hospitalières de Acinetobacter baumanii. Pathol Biol (Paris) 1989 Jun;37(5 Pt 2):612–616.
Joly-Guillou ML, Bergogne-Bérézin E. Activité comparative in vitro du ceftizoxime, de la ceftazidime et de l'imipenem sur Acinetobacter calcoaceticus. Pathol Biol (Paris) 1986 Jun;34(5 Pt 2):625–628.
Joly-Guillou ML, Bergogne-Berezin E. Présence d'une beta-lactamase à spectre élargi chez Acinetobacter baumanii. Presse Med. 1990 Apr 7;19(14):672–673.
Joly-Guillou ML, Bergogne-Berezin E, Vieu JF. Epidémiologie et résistance aux antibiotiques des Acinetobacter en milieu hospitalier. Bilan de 5 années. Presse Med. 1990 Mar 3;19(8):357–361.